Natco Pharma
 | |
| Company type | Public company |
|---|---|
| NSE: NATCOPHARM | |
| Industry | Pharmaceuticals |
| Founded | 1981 |
| Founders | VC Nannapaneni |
| Headquarters | , |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
| Website | natcopharma.co.in |
Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India,[3] and among the country's top three in producing hepatitis C drugs.[4]
In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[5] In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[4]
In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[5]
References
- ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
- ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
- ^ "Natco Pharma lines up 20 `Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
- ^ a b "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
- ^ a b "Niche Play". Business Today. Retrieved 19 April 2020.
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |